AVI-4557 Neugene: Phase I

In a Phase I study of a single intravenous dose of 300 mg AVI-4557 in healthy volunteers, AVI-4557 down-regulated cytochrome P450 3A4, resulting in a reduction in the breakdown of midazolam. ...